<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6693">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02088203</url>
  </required_header>
  <id_info>
    <org_study_id>RT2</org_study_id>
    <nct_id>NCT02088203</nct_id>
  </id_info>
  <brief_title>Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)</brief_title>
  <official_title>Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Complex as a Dietary Supplement to Improve Carbohydrate Metabolism; Dosing, Safety and Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plants from the genus Artemisia, and specifically Artemisia dracunculus L. (Russian
      tarragon) have had a long history of medicinal (health) and culinary (food) use and have
      been reported as effective as a traditional treatments for diabetes in various parts of the
      world. The overall objective of this study is to conduct early human investigation and to
      evaluate the effect of nutritional supplementation with a well characterized extract of
      Artemisia dracunculus L. The primary objectives would be to evaluate safety, tolerability
      and effective dose in non-diabetic human subjects. Secondary objectives would assess
      metabolism of the extract and evaluate effects on proposed mechanisms such as insulin
      secretion, lipid levels and/or insulin resistance.

      After completing a screening visit and meeting qualifications for the single oral dose
      evaluation, subjects will receive three single doses (two different doses of the supplement
      and one dose of placebo) on three separate test periods which are separated by a washout
      period of at least 7 days. Each testing period requires an overnight stay on the inpatient
      unit. The inpatient stay will be approximately 26 hours. The doses that will be used in the
      study are 0.3, 1, 3, 10, 20 and 30 grams plus the placebo. The supplement and the placebo
      will be mixed with sugar-free flavoring in water. There will be an opportunity to sample the
      liquid drink during the screening visit.

      Screening visit 1 (about 1 hour) - Fasting (Nothing to eat or drink other than water for at
      least 10 hours prior to appointment)

        -  Sign informed consent if willing to participate

        -  Body weight and height will be measured (body mass index will be calculated from these
           measures)

        -  Blood pressure, pulse and temperature will be measured

        -  Physical exam and ECG (electrocardiogram)

        -  Report any medications taken over the past 3 months

        -  Blood draw (about 2 teaspoons) to assess overall health

        -  Taste test

      ALL PROCEDURES AND VISITS LISTED BELOW WILL BE REPEATED 3 TIMES. ALL TESTING WILL BE DONE
      FOR EACH SINGLE DOSE TESTING PERIOD (1,2,3)

        -  Testing Period 1: Day -3, Day 1, Day 2

        -  7 Day Washout

        -  Testing Period 2: Day -3, Day 1, Day 2

        -  7 Day Washout

        -  Testing Period 3: Day -3, Day 1, Day 2

      Day -3 (about 4 hours) Fasting (Nothing to eat or drink other than water for at least 10
      hours prior to appointment)

        -  Blood pressure, pulse and temperature will be measured

        -  An IV line will be placed in an arm vein for blood draw purposes and will remain there
           throughout the testing.

        -  A blood draw (approximately 2 teaspoons) will be done before and after dosing to assess
           any changes in glucose or insulin.

        -  An Oral Glucose Tolerance Test (OGTT) will be done A blood sample will be drawn from
           the IV line, and then the subject will drink a sugar solution consisting of 75 grams of
           glucose. Blood will be drawn at specific times after the drink is consumed. Each blood
           sample will be about 1 tablespoon. (6 tablespoons total for the test). During the IV
           procedure, a small amount of the subject's own blood (less than 1 teaspoon) will
           immediately be returned into the vein through the IV after each specimen is collected.

        -  Adverse events and changes in medication will be assessed by the staff

        -  Meet with staff briefly about dietary intake and weight maintenance diets

      Day 1 (Inpatient Stay- 26 hours) Fasting (Nothing to eat or drink other than water for at
      least 10 hours prior to appointment)

        -  Admission to the inpatient unit in the morning of the Day 1 visit. The subject will
           remain on the unit overnight and be discharged on Day 2.

        -  Blood pressure, pulse and temperature will be measured.

        -  Randomization to the study dosing scheme will occur. Randomization is like flipping a
           coin. You and the study staff will not know what dose you are receiving or if you are
           receiving placebo (inactive pill).

        -  Single dose of extract given (either the supplement or placebo). The dose will be given
           2 hours prior to the start of the OGTT. The extract will be in a powder form and will
           be mixed with up to 8 ounces of liquid for you to drink.

        -  An IV line will be placed in the arm vein for blood draw purposes and will remain there
           throughout the testing.

        -  OGTT as described above (at day -3).

        -  A blood draw (approximately 2 teaspoons) before and after dosing will be done to assess
           any changes in glucose or insulin. Blood draws will occur at 30, 60, 90, 120, 180, 240
           minutes and 12 hours after dosing.

        -  An ECG performed will be performed.

        -  Adverse events and changes in medication will be assessed by the staff.

        -  The subject will be asked to fast overnight until your blood work on Day 2.

      Day 2 (Inpatient) Blood pressure, weight, pulse and temperature will be measured.

        -  A physical exam will be done

        -  A 24 hour post dose blood draw (approximately 1 teaspoon) will be done.

        -  Study staff will schedule the next testing period if applicable and then the subject
           will be discharged from the inpatient unit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Levels of bioactive components from the Russian Tarragon Nutrasorb in the blood and urine</measure>
    <time_frame>on average weekly for 3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance measured with an OGTT</measure>
    <time_frame>on average weekly for 3 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Diabetes Prevention</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Russian Tarragon Nutrasorb 0.3g, Russian Tarragon Nutrasorb 1g, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Russian Tarragon Nutrasorb 0.3g, Placebo, Russian Tarragon Nutrasorb 1g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, Russian Tarragon Nutrasorb 0.3g, and Russian Tarragon Nutrasorb 1g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Russian Tarragon Nutrasorb 3g, Russian Tarragon Nutrasorb 10g, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Russian Tarragon Nutrasorb 3g, Placebo, Russian Tarragon Nutrasorb 10g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, Russian Tarragon Nutrasorb 3g, Russian Tarragon Nutrasorb 10g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Russian Tarragon Nutrasorb 20g, Russian Tarragon Nutrasorb 30g, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Russian Tarragon Nutrasorb 20g, Placebo, Russian Tarragon Nutrasorb 30g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, Russian Tarragon Nutrasorb 20g, Russian Tarragon Nutrasorb 30g</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Russian Tarragon Nutrasorb</intervention_name>
    <description>Russian Tarragon Nutrasorb 0.3 g</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Russian Tarragon Nutrasorb</intervention_name>
    <description>Russian Tarragon Nutrasorb 1 g</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Russian Tarragon Nutrasorb</intervention_name>
    <description>Russian Tarragon Nutrasorb 3 g</description>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Russian Tarragon Nutrasorb</intervention_name>
    <description>Russian Tarragon Nutrasorb 10 g</description>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Russian Tarragon Nutrasorb</intervention_name>
    <description>Russian Tarragon Nutrasorb 20 g</description>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Russian Tarragon Nutrasorb</intervention_name>
    <description>Russian Tarragon Nutrasorb 30 g</description>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are an overall healthy adult

          -  Are male or female, ages 18-65 at time of consent

          -  Are female and of childbearing potential, you must agree to use one of the approved
             contraception method [(i.e., barrier method, intrauterine and cervical devices, oral
             contraceptives, hormonal injections (Depo ProveraÂ®), condoms with spermicidal gel or
             foam, contraceptive patch (Ortho Evra), diaphragm, or abstinence)], prior to the
             start of dosing to sufficiently minimize the risk of pregnancy at that point. Female
             subjects must agree to use contraception until the follow-up visit.

          -  Have a BMI within the range 18.5-32 kg/m2 (this is a measure of your height to weight
             ratio).

          -  Are capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Have no significant cardiac, pulmonary, gastrointestinal, hepatic, renal,
             hematological, endocrine, neurological and psychiatric disease

          -  Have overall normal clinical laboratory tests as deemed by the physician

        Exclusion Criteria:

          -  Have a prior history of Type 1 or 2 diabetes

          -  Are a female who is pregnant or lactating.

          -  Are taking certain medications (these will be reviewed with you by the study staff).

          -  Are anticipating or planning to have surgery during the study period.

          -  Are a current smoker or have smoked within the previous 6 months.

          -  Have had a weight change of more than 5% in the last 2 months.

          -  Are taking prescription or over the counter medications or supplements for weight
             loss.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>recruiting</last_name>
      <phone>225-763-3000</phone>
      <email>doctors@pbrc.edu</email>
    </contact>
    <investigator>
      <last_name>William T. Cefalu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Hsia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Rood, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>William Cefalu, MD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
